Article Preview As the sophistication of operational practices across life sciences increases; unfortunately, so do the difficulty and complexity of

Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

Article Preview Determining customer satisfaction and loyalty is a difficult endeavor for most businesses. Traditional voice of customer surveys are

Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

Article Preview Arup Laboratories announced it will begin offering next-generation sequencing (NGS) based high resolution Human Leukocyte Antigen (HLA) genotyping

Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion

Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies

Article Preview Germany’s Merck KGaA has announced the acquisition of Sigma-Aldrich Corporation, a global life sciences tools (LST) firm, based

Article Preview Laboratory Corporation of America Holdings is making a strong bid to expand its personalized medicine offering by adding